Osteoclasts modulate bone resorption under physiological and pathological conditions. Previously, we showed that both estrogens and retinoids regulated osteoclastic bone resorption and postulated that such regulation was directly mediated through their cognate receptors expressed in mature osteoclasts. In this study, we searched for expression of other members of the nuclear hormone receptor superfamily in osteoclasts. Using the low stringency homologous hybridization method, we isolated the peroxisome proliferator-activated receptor ␦/ (PPAR␦/) cDNA from mature rabbit osteoclasts. Northern blot analysis showed that PPAR␦/ mRNA was highly expressed in highly enriched rabbit osteoclasts. Carbaprostacyclin, a prostacyclin analogue known to be a ligand for PPAR␦/, significantly induced both bone-resorbing activities of isolated mature rabbit osteoclasts and mRNA expression of the cathepsin K, carbonic anhydrase type II, and tartrate-resistant acid phosphatase genes in these cells. Moreover, the carbaprostacyclin-induced bone resorption was completely blocked by an antisense phosphothiorate oligodeoxynucleotide of PPAR␦/ but not by the sense phosphothiorate oligodeoxynucleotide of the same DNA sequence. Our results suggest that PPAR␦/ may be involved in direct modulation of osteoclastic bone resorption.Mature osteoclasts are differentiated from hemopoietic stem cells and fuse each other into multinucleate giant cells. These cells are characterized by a combination of some unique properties. They possess tartrate-resistant acid phosphatase (TRAP) 1 activity, an abundance of cathepsin K, and highly developed ion transport systems (1, 2). Mature osteoclasts are involved in bone metabolism, especially they resorb mineralized bone surfaces under both physiological and pathological conditions (3).Much evidence obtained from in vitro studies has demonstrated that the differentiation of osteoclasts is controlled by various factors, such as vitamin D 3 , osteoclast differentiation factor, osteoclastogenesis inhibitory factor, macrophage colonystimulating factor, and parathyroid hormone (4 -7). The osteoclast is also active in postmenopausal osteoporosis (bone loss), a major health problem (2). Estrogen deficiency has long been recognized as a cause of postmenopausal osteoporosis, and estrogen replacement therapy is an effective treatment for the prevention of bone loss. Research has shown that estrogen loss promotes interleukin-6 secretion in nonosteoclastic cells and that interleukin-6 up-regulates osteoclast differentiation and formation (8,9). However, the function and metabolism of fully mature osteoclasts remain unclear, especially at the molecular level, because of the difficulty in obtaining large quantities of highly enriched osteoclasts for use in such in vitro studies.For assessment of the bone-resorbing activity of mature osteoclasts, it would be desirable to have a cell suspension consisting of highly enriched mature osteoclasts that could be cultured on a mineralized substratum such as a bone or dentine ...